anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary artery pressure with significant morbidity and mortality. Inflammatory processes are crucial in PAH pathogenesis, with inflammatory cells and mediators present early in disease progression. IL-34 involvement in inflammatory pathways suggests that IL-34 could be an important player in the progression of PAH, influencing both pulmonary pressures and vascular changes.
OBJECTIVE: The purpose of this study was to investigate the correlation between IL-34 levels and pulmonary arterial hypertension (PAH), aiming to enhance the understanding of the molecular mechanisms underlying PAH and explore IL-34's potential as a biomarker.
METHODS: Consecutive PAH patients diagnosed via right-heart catheterization at Malatya Turgut Ozal Eğitim ve Araştırma Hastanesi (Dec 2022 - Apr 2024) were enrolled. Patients were classified into low-risk and high-risk groups based on comprehensive risk assessments that included clinical parameters, hemodynamic measurements and biomarkers, in-line with ESC/ERS guidelines. Serum IL-34, hs-CRP, and NT-proBNP levels were measured and compared with those of healthy controls. Echocardiographic assessments and statistical analyses, including ROC analysis, were conducted to evaluate biomarker significance and predictive capabilities.
RESULTS: The mean age of low-risk and high-risk PAH patients was 42 ± 7.2 years and 45 ± 5.5 years, respectively. The mean age of the control group was 40 ± 6.4 years. Males comprised 54.29 % of the low-risk group, 56 % of the high-risk group, and 53.3 % of the control group. IL-34 and hs-CRP levels were significantly elevated in PAH patients compared to controls. IL-34 correlated positively with systolic pulmonary artery pressure, RA area, and NT-proBNP levels. Multivariate analysis revealed that IL-34 and hs-CRP were independent predictors of PAH. IL-34 levels>29.8 pg/mL predicted PAH with 78 % sensitivity and 69 % specificity, while levels >44.4 pg/mL predicted high-risk PAH with 84 % sensitivity and 77 % specificity.
CONCLUSION: Elevated IL-34 and hs-CRP levels are associated with PAH severity and right ventricular dysfunction, suggesting IL-34's potential as a diagnostic and prognostic biomarker. Further research is needed to validate these findings and explore IL-34-targeted therapies in pH management.
There have been post-marketing reports of severe skin and hepatic adverse events associated with griseofulvin use (see WARNINGS section).

When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria, erythema multiforme-like drug reactions, and rarely, angioneurotic edema, and may necessitate withdrawal of therapy and appropriate countermeasures. Paresthesia of the hands and feet have been reported after extended therapy. Other side effects reported occasionally are oral thrush, nausea, vomiting, epigastric distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion, and impairment of performance of routine activities. Proteinuria and leukopenia have been reported rarely. Administration of the drug should be discontinued if granulocytopenia occurs. When rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The hypothalamus is the key regulator for energy homeostasis and is functionally connected to striatal and cortical regions vital for the inhibitory control of appetite. Hence, the ability to non-invasively modulate the hypothalamus network could open new ways for the treatment of metabolic diseases. Here, we tested a novel method for network-targeted transcranial direct current stimulation (net-tDCS) to influence the excitability of brain regions involved in the control of appetite. Based on the resting-state functional connectivity map of the hypothalamus, a 12-channel net-tDCS protocol was generated (Neuroelectrics Starstim system), which included anodal, cathodal and sham stimulation. Ten participants with overweight or obesity were enrolled in a sham-controlled, crossover study. During stimulation or sham control, participants completed a stop-signal task to measure inhibitory control. Overall, stimulation was well tolerated. Anodal net-tDCS resulted in faster stop signal reaction time (SSRT) compared to sham (p = 0.039) and cathodal net-tDCS (p = 0.042). Baseline functional connectivity of the target network correlated with SSRT after anodal compared to sham stimulation (p = 0.016). These preliminary data indicate that modulating hypothalamus functional network connectivity via net-tDCS may result in improved inhibitory control. Further studies need to evaluate the effects on eating behavior and metabolism.
PURPOSE:To obtain the titled substance having high immunospecific purity, in high efficiency by single absorption and desorption process, by using an adsorbent bonded with a monoclonal antibody obtained from a hybridoma cell produced by cell fusion. CONSTITUTION:The spleen cell of a mouse immunized with human transferrin (Tf) is fused with a myeloma cell by cell fusion to obtain a hybridoma cell, from which a monoclonal anti-human-Tf antibody is produced. The antibody is bonded to an adsorbent [e.g. Affigel (product of Biolad Corp.), etc.], and the obtained adsorbent is made to contact with human serum or plasma to effect the adsorption of human Tf. The adsorbed human Tf is desorbed to obtain a high- purity human Tf. Since the antibody in the adsorbent bonded with antibody is a monoclonal antibody of human Tf, the quality of the antibody is uniform, the hybridoma cell producing said antibody can be preserved in frozen state, and the antibody is available easily and stably. The used adsorption column can be regenerated and reused about 10 times.
The effectiveness of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) have been addressed for the treatment of peritoneal carcinomatosis in selected patients. However, prophylactic HIPEC in colorectal cancer patients at high risk of metachronous peritoneal metastases remained controversial. In this study, patients with colorectal cancer cT4N0-2M0(AJCC/UICC staging system 8th edition) and planed to undergo intentionally colectomy (laparotomy, laparoscopy，or robotic ) are randomized into HIPEC group and control group. In HIPEC group, closed HIPEC is performed with Mitomycin C(30mg/m2) at 43 °C for 90 minutes, simultaneously or within 2 days after colectomy and followed by systemic chemotherapy. For the patients in the control group, systemic chemotherapy were administered after colectomy. The primary endpoint is peritoneal recurrence-free survival (pRFS) rate. Secondary end points include overall survival (OS) rate, disease free survival (DFS) rate, liver metastatic rate, toxic effects, quality of life scores. All efficacy analyses are conducted in the intention-to-treat population, per-protocol population and pT4 subgroups due to pathologic tumor invasion can not be acquired before HIPEC. Safety analysis include only patients who receive their randomly assigned treatment.
Vitiligo is a common autoimmune disease characterized by patches of depigmented skin and overlying hair due to destruction of melanocytes in the involved regions. We investigated the relationship between vitiligo risk and vitiligo age of onset (AOO) using a vitiligo polygenic risk score that incorporated the most significant SNPs from genome-wide association studies. We find that vitiligo genetic risk and AOO are strongly inversely correlated; subjects with higher common-variant polygenic risk tend to develop vitiligo at an earlier age. Nevertheless, the correlation is not simple. In individuals who carry a single high-risk major histocompatibility complex class II haplotype, the effect of additional polygenic risk on vitiligo AOO is reduced. Particularly among those with early-AOO vitiligo (onset ≤12 years of age), genetic risk can reflect contributions from high common-variant burden but also rare variants of high effect and sometimes both. While the heritability of vitiligo is relatively high, and we here show that genetic risk factors predict vitiligo AOO, vitiligo is never congenital, and thus environmental triggers also play an important role in disease onset.
A total of 100 eyes of 50 patients with TGD and 100 eyes of 50 healthy controls were enrolled. Diagnosis of TGD was based on history, clinical examination and laboratory investigations. Exclusion criteria included previous thyroid medications, thyroidectomy, previous ocular surgery, corneal pathology and other risk factors of keratoconus (KC). All eyes were examined by Pentacam, (Oculus Optikgerate GmbH, Wetzlar, Germany). Pentacam parameters were compared between TGD patients and controls. Spearman's correlation coefficient between different pentacam parameters and the level of free T4 and TSH was calculated.
Over a 6 month period, we will ask study participants to take both Niagen or a placebo for 8 weeks each and complete research visits ever 4 or 8 weeks. Most research visits will involve a blood draw, cognitive testing, and mood questionnaires. Most study activities will take place via Zoom videoconferencing. We will ask you to come to our center 4-5 times to complete some study activities in-person. There will be an option to participate in a lumbar puncture sub-study, in which participants would have up to 3 lumbar punctures. There will also be an option to participate in an MRI sub-study, in which participants would have up to 3 MRIs over the course of the study. In between research visits, we will also ask the participants to wear a Fitbit activity tracker and play computerized brain games a few times a week. This will enable us to get a snapshot of each subject's functioning levels day to day and better determine whether or not the supplement is having an effect on the participant.
The present application relates to methods of treating a subject for cancer. The method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics in the subject. The first and second agents are administered no more than eight hours apart from each other, to the subject to treat cancer. As a result of the administering, the amount of first and second cancer therapeutic component internalized and retained within a tumor is greater than the sum of first and second cancer therapeutic component internalized and retained in a tumor if each of the first and second agents were administered alone. Also disclosed is a combination therapeutic comprising the first and second agents blended togeth
<P>PROBLEM TO BE SOLVED: To effectively utilize a root and a leaf of Gentiana triflora which are conventionally discarded.  <P>SOLUTION: The anticancer agent as an oral medicine or an external preparation contains a crude extract of a plant of Gentiana spp, or a purified product obtained therefrom as an active ingredient. The Gentiana triflora is preferably used as the Gentiana spp. The root or the leaf, especially the root is preferably used as the part of the plant. The crude extract or the purified product can be used as the health assistant food (supplement) and the cosmetic for medicinal use.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Participants will receive oral nifedipine for blood pressure control. Dosage may initially start at one 10mg capsule by mouth three times per 24 hours (total of 30mg a day), however dosage may be increased by 30mg increments (i.e. 20mg capsule three times a day for a total of 60mg a day). Maximum dosage for oral Nifedipine will be 120mg per day.
PURPOSE:To obtain the title composition having high safety, reduced stimulative property to skin and hair and mild action and having excellent foaming force and cleaning force by combining a specific anionic surfactant with a specific amphoteric surfactant. CONSTITUTION:The aimed cleaning composition having low stimulative property and containing an anionic surfactant [e.g. palm oil fatty acid sulfuric acid sodium salt of N-polyoxyethylene(4EO) palm oil fatty acid sulfuric acid sodium salt] expressed by formula I (R1 is 7-17C alkyl or alkenyl; M1 is alkali metal; n is 2-5) and amphoteric surfactant [e.g. 2-[dimethyl(2-hydroxy-3-desiloxypropyl) ammonio]ethylphosphate, etc.] as active ingredients. The aimed composition has remarkably low stimulative property to skin while satisfying essential conditions as a cleaning agent such as foaming property and cleaning property.
Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
Crohn's disease (CD) is a chronic immune-mediated disorder of the gastrointestinal tract. Extensive screening studies have revealed the accumulation of immune cell subsets with unique plasticity and immunoregulatory properties in patients with CD. We performed phenotypic and functional studies on inflamed and non-inflamed bioptic tissue to investigate the presence of distinct T cells in the intestinal mucosa of CD patients. We analysed hundreds of surface molecules expressed on cells isolated from the intestinal tissue of CD patients using anti-CD45 mAbs-based barcoding. A gene ontology enrichment analysis showed that proteins that regulate the activation of T cells were the most enriched group. We, therefore, designed T-cell focused multicolour flow-cytometry panels and performed clustering analysis which revealed an accumulation of activated TEM CD4+CD39+ T cells producing IL-17 and IL-21 and increased frequency of terminally differentiated TCR Vδ1+ cells producing TNF-α and IFN-γ in inflamed tissue of CD patients. The different functional capacities of CD4+ and TCR Vδ1+ cells in CD lesions indicate their non-overlapping contribution to inflammation. The abnormally high number of terminally differentiated TCR Vδ1+ cells suggests that they are continuously activated in inflamed tissue, making them a potential target for novel therapies.
Patients in the PVI group will be started on maintenance fluid therapy at 2-3 ml / kg / hour. In addition to standard monitoring, if PVI is \<13% and OAB≥65mmHg in measurements made with PVI, current fluid therapy will continue. If PVI is \<13% and MAP \<65 mmHg, noradrenaline infusion will be started. If PVI is\> 13% and OAB≥65 mmHg, 250 ml iv colloid bolus will be administered, and iv colloid bolus will be continued until the PVI is \<13% in the 5-minute follow-ups. If PVI\> 13% and MAP \<65 mmHg, patients should receive 250 ml i.v. colloid infusion will be given, if MAP \<65mmHg continues in 5 minutes follow-up, 250 ml i.v. Colloid and noradrenaline infusion will be started and repeated until the OAB≥65 mmHg and PVI \<13%.
The dose of Sonata should be individualized. The recommended dose of Sonata for most nonelderly adults is 10 mg. For certain low weight individuals, 5 mg may be a sufficient dose. Although the risk of certain adverse events associated with the use of Sonata appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Doses above 20 mg have not been adequately evaluated and are not recommended. 

Sonata should be taken immediately before bedtime or after the patient has gone to bed and has experienced difficulty falling asleep (see PRECAUTIONS.). Taking Sonata with or immediately after a heavy, high-fat meal results in slower absorption and would be expected to reduce the effect of Sonata on sleep latency (see Pharmacokinetics under CLINICAL PHARMACOLOGY). 

Special Populations 

Elderly patients and debilitated patients appear to be more sensitive to the effects of hypnotics, and respond to 5 mg of Sonata. The recommended dose for these patients is therefore 5 mg. Doses over 10 mg are not recommended. 

Hepatic insufficiency: Patients with mild to moderate hepatic impairment should be treated with Sonata 5 mg because clearance is reduced in this population. Sonata is not recommended for use in patients with severe hepatic impairment. 

Renal insufficiency: No dose adjustment is necessary in patients with mild to moderate renal impairment. Sonata has not been adequately studied in patients with severe renal impairment. 

An initial dose of 5 mg should be given to patients concomitantly taking cimetidine because zaleplon clearance is reduced in this population (see Drug Interactions under PRECAUTIONS).
PURPOSE: A strain producing conjugated linoleic acid isolated from first milk is provided to ensure excellent conjugated linoleic acid producing ability without resistance to vancomycin antibiotic. CONSTITUTION: An Enterococcus faecalis strain produces conjugated linoleic acid. The deposit number of the strain is Enterococcus faecalis JBMI Ca009(deposit number KACC 91590P). The strain is isolated from human first milk and has one or more characteristic of acid resistance, bile acid resistance, and thermal resistance. A microorganism agent for producing the conjugated linoleic acid contains the Enterococcus faecalis or culture liquid thereof as an active ingredient. A functional food contains the strain or culture liquid thereof as an active ingredient.
1. Use of a compound having the formula wherein R1 is hydrogen or -COCH3, and R2 is hydrogen or C1-2 alkyl, or a prodrug thereof for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases. 2. Use according to claim 1, characterized in that the compound having the formula (I) is paracetamol. 3. Use according to claim 1, characterized in that the prodrug of paracetamol is proparacetamol, aminosalol or acetaminosalol or acetaminosalol glycine ester. 4. Use according to claim 1 or 2, characterized in that the disease is Alzheimer's disease. 5. A therapeutic method in which a patient suffering from a neurodegenerative disease is treated with a therapeutically useful quantity of a compound having the formula wherein R1 is hydrogen or -COCH3, and R2 is hydrogen or C1-2 alkyl, or a prodrug thereof. 6. A method according to claim 4, characterized in that the disease is Alzheimer's disease. 7. Use according to claims 4 or 5, characterized in that the compound having the formula (I) is paracetamol. 8. A method according to claim 4, wherein the treatment comprises daily administration of 0.01-200 mg/kg of a compound having the formula (I) or an equivalent quantity of a prodrug of paracetamol. 9. A method according to claims 4 to 6, wherein the treatment comprises daily administration of 10-100 mg/kg of paracetamol or an equivalent quantity of a prodrug thereof. 10. A method according to claim 8, wherein the treatment comprises daily administration of 15-75 mg/kg of paracetamol or an equivalent quantity of a prodrug thereof.
OBJECTIVE: Health-related quality of life (HRQoL) is an important indicator of population health and can measure the impact of medical actions. The main objective of this study was to determine the HRQoL of patients with rheumatic diseases (RD) and compare it with that of the general population.
METHODS: Observational, cross-sectional, single-center study, with consecutive inclusion of outpatients over 18 years of age seen at a Rheumatology hospital-based outpatient clinic in Madrid. Sociodemographic, clinical variables and HRQoL were recorded. HRQoL was measured with the 5-dimension, 5-level EuroQoL (EQ-5D-5L), which includes the EQ-Index (0-1 scale) and a visual analog scale (VAS, 0-100 scale). A descriptive analysis and a comparison with the HRQoL of the Spanish general population were performed.
RESULTS: 1144 patients were included, 820 (71.68%) women, with a mean age of 56.1 years (range 18-95), of whom 241 (25.44%) were new patients. In patients with RD, the HRQoL measured with the EQ-Index and with the VAS, was 0.186 and 12 points lower, respectively, than in the general population. The decrease in HRQoL affected the 5 health dimensions, especially "pain/discomfort", followed by "daily activities" and "mobility". This reduction in HRQoL was observed in both men and women, and in all age ranges, although it was greater between 18 and 65 years of age. The reduction in HRQoL affected all RD subtypes, especially the "peripheral and axial mechanical pathology" and the "soft tissue pathology" group.
CONCLUSIONS: Patients with rheumatic diseases report worse HRQoL when compared to the general population in all dimensions of HRQoL.
NEW MATERIAL:Krebs statika (KBS for short) (an antitumor substance derived from human) (molecular weight: 82,000+ or -10,000; isoelectric point: 6.5+ or -0.5). USE:An antitumor substance. PREPARATION:A normal cell of a monocyte cell (e.g., cancerized cell of monocyte macrophage system derived from human, etc.) which is treated with the first irritation substance (conditioned culture solution of lymphocyte system or lyophoblast system, chemical substance differentiating and inducting leukocyte, natural extract, etc.) in a tissue culture system or its cancerized cell is treated with the second irritation substance (endotoxin obtained from Gram-positive or Gram-negative bacteria; polysaccharide, etc. derived from Escherichia coli, Pseudomonas aeruginosa, etc. to give KBS, and it is collected. KBS is orally or parenterally administered. A daily dose is >=10,000 units/person. A cytotoxic effect on normal human cell is hardly observed.
Small particles of a weakly acidic organic cpd (I) whose solubility in water is greater at a first pH than a second pH are prepd. by dissolving the cpd. in water at the firstpH, pref. 2 pH units above the pKa of the cpd., which also  contains an anionic or cationic surfactant which keeps its ionic nature at both pH and an amphoteric surfactant whose cationic nature increases from the first pH to the second. The mixt. is stirred and the pH reduced to the second pH causing  a coacervate of the two surfactants and pptn. of (I) as fine particles. - The cpds. include sulphadiazine, lidocaine, salicylic acid, felodipine, sulbactam, pivoxil, chlorzoxazone, theophylline or erythromycin.
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to substances preventing malignant regeneration of mammal (including human) normal cells in malignant cells. Aaptos sp. sponge is used to produce an aaptamine analogue, namely 3-N-morpholinyl-9-demethyloxyaaptamine exhibiting ability to prevent mammal normal cell transformation in malignant cells. What is offered is use of 3-N-morpholinyl-9-demethyloxyaaptamine, and also its analogues 9-demethyloxyaaptamine, isoaaptamine, 3-phenethylamino-9-demethyl oxyaaptamine and 3-isopentyl amino-9-demethyloxyaaptamine as such agent. Besides, these substances are used for preparing pharmaceutical compositions preventing mammal normal cell transformation in malignant cells. 3-N-morpholinyl-9-demethyloxyaaptamine and its analogues have a cancer-preventive effect in the concentration nontoxic for normal cells. ^ EFFECT: reduced risk of toxic action on body after prolonged administration of the substances. ^ 3 cl, 1 dwg, 10 tbl, 7 ex